A study to assess Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients.
Phase 3
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/03/032072
- Lead Sponsor
- MARC Laboratories Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Age > 18 years
2. Written Informed consent is documented
3. COVID-19 positive clinical symptoms and (subsequently) confirmed by the current recommended confirmatory test (RT PCR).
4. Can take oral medicines.
5. Mild-moderate grade of the disease.
Exclusion Criteria
1. Known sensitivity to any of the ingredients
2. Bleeding haemorrhoids
3. Serious stages of the illnesses
4. ICU admitted patients
5. Pre-existing GI symptoms like nausea or vomiting
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical status as assessed with the seven-category ordinal scale on days 7 and 14Timepoint: Day1, Day 7 and Day14
- Secondary Outcome Measures
Name Time Method 1. Laboratory parameters for Serum C - reactive protein (CRP, Hb, Total leukocyte count and differential leukocyte count. <br/ ><br>2.Fever to normal temperature in days. <br/ ><br>3.Time to negative PCR days. <br/ ><br>4. Change in LFT ParametersTimepoint: Day1 and Day14